分类： ACN Newswire

香港, 2026年4月20日 - (亚太商讯 via SeaPRwire.com) - 生物医药产业是国家战略性新兴产业的核心组成部分，也是守护人类生命健康的关键屏障，迈威生物作为行业内领先企业，于4月20日正式启动招股程序，距港交所上市再进一步。 研发创新持续加码，构筑差异化竞争壁垒据悉，成立于2017年的迈威生物，是一家以药物研发方面的创新能力以及从药物发现至商业化销售的综合能力而闻名的中国制药公司。公司拥有雄厚的自主创新能力，专注于打造可有效应对临床挑战的差异化产品，以技术创新突破临床治疗瓶颈，为患者带来更优质、更高效的治疗选择。抗体偶联技术创新，是迈威生物于 ADC 领域的核心优势，亦是公司构建差异化竞争力的关键支撑。公司长期深耕 ADC 技术研发，已搭建起具备自主知识产权的四大核心ADC技术，涵盖DARfinity、IDconnect、Mtoxin及LysOnly，具体而言，DARfinity为公司自主研发的定点偶联工艺；IDconnect是一种经过优化设计的连接符分子，用以连接抗体和毒素，使抗体和毒素之间的连接更稳定；Mtoxin为一种基于喜树碱的新型毒性分子，用作ADC中杀死靶细胞的「弹头」；LysOnly则是一种能够有条件释放毒素的结构，可提高ADC的整体安全性和有效性。这四大核心ADC技术形成完备的技术体系，为产品管线持续迭代升级筑牢坚实基础。依托核心技术优势，迈威生物构建了一组多元化的创新ADC产品管线，包括9MW2821、7MW3711和7MW4911等重点候选产品，每种产品针对不同的肿瘤相关抗原，精准覆盖不同类型肿瘤的治疗需求，形成了全面的产品矩阵。其中，为克服尿路上皮癌、三阴性乳腺癌、宫颈癌和食管癌治疗的局限性，迈威生物开发了9MW2821，这是一款靶向Nectin-4的新一代ADC，可作为单药亦或联合疗法中的主要药物。相较于已上市的Padcev，9MW2821在尿路上皮癌患者的治疗中展现出更优的疗效，同时凭借独特的技术优势，有望成为针对三阴性乳腺癌、宫颈癌和食管癌的同类型最佳靶向Nectin-4 ADC，市场前景广阔，将为公司带来显著的业绩增长动力。此外，7MW3711是一款靶向B7-H3 ADC，主要用于治疗晚期实体瘤，国家药监局于2023年7月批准7MW3711针对晚期实体瘤患者的临床试验的IND申请，标志着该产品正式进入中国临床开发阶段；FDA于2024年2月批准7MW3711在美国进行临床开发，并于2024年7月授予用于治疗小细胞肺癌的ODD，为产品在美国市场的后续开发与商业化奠定了坚实基础。公司分别于2023年8月及2023年9月，在中国启动7MW3711单药用于治疗晚期实体瘤患者的两项I/II期临床试验，进展顺利；于2026年2月，启动7MW3711联合JS207（PD-1）或JS207及抗肿瘤疗法，治疗晚期实体瘤患者的Ib/II期临床试验，进一步拓展产品的应用场景，巩固公司在ADC领域的领先地位。7MW4911是特异性靶向CDH17的新一代ADC，临床前研究表明，7MW4911能有效结合肿瘤细胞上的CDH17，引发快速内化，并选择性释放细胞毒性载荷，从而最大程度减少对正常组织的损伤，安全性与有效性均表现优异。对于针对晚期实体瘤的7MW4911单药疗法，公司于2025年11月在中国启动I期临床试验，并于2026年1月在美国启动I/II期临床试验，加速推进产品的全球临床布局，未来将为公司全球化发展注入新的活力，进一步扩大公司的市场影响力。深耕单抗领域，拓展业务领域除ADC领域外，迈威生物在单抗领域亦不断深耕与创新，多款管线产品均针对前景广阔但较少探索的靶点，填补临床治疗空白。公司的关键产品9MW1911是一款靶向ST2的单抗，旨在治疗COPD、哮喘和特应性皮炎等自身免疫性疾病，精准切入未被满足的临床需求领域。截至最后实际可行日期，全球尚无针对非Th2通路表型COPD的生物疗法获得批准，9MW1911作为在中国临床开发阶段进展最快的，首款自主研发靶向非Th2通路大分子药物。从市场前景来看，中国COPD药物市场规模庞大，市场规模从2019年的人民币199亿元增长到2024年的人民币223亿元，复合年增长率为2.3%，预计将加速增长至2028年的人民币262亿元及2032年的人民币584亿元，2024年至2028年及2028年至2032年的复合年增长率分别为4.0%及22.2%，行业具备着广阔成长空间，9MW1911有望打开临床治疗缺口，为广大COPD患者带来新的治疗希望。此外，9MW3811是用于纤维化相关疾病及癌症治疗的靶向IL-11的人源化单抗，公司对9MW3811的Fc区实施化学修饰，以降低Fc介导毒性的潜在风险并延长其半衰期，进一步提升产品的安全性与疗效，彰显公司在单抗领域的研发实力与创新理念，为公司构建多元化的产品管线、拓展业务边界提供了有力支撑。值得注意的是，此前因该品种IL-11在抗衰老方面的潜力，迈威生物已将其除大中华区以外的所有区域独家开发、生产和商业化的权利授予Calico Life Sciences LLC，根据合作协议，公司将获得一次性不可退还的首付款2500万美元、合计最高达5.71亿美元的近期、开发及商业化里程碑付款以及按净销售额计算的特许权使用费。据悉，Calico是一家美国公司及Alphabet Inc.的子公司，专注于创新型抗衰老疗法的研发，并在涉及IL-11疗法的抗衰老药物开发方面具有丰富经验。总体而言，迈威生物凭借深厚的研发积淀、自主创新的核心技术、多元化的优质产品管线以及完善的商业化布局，在行业内建立了坚实的行业地位，展现出强劲的增长潜力。此次赴港上市，公司有望借助资本市场的力量，加速推进核心产品的临床开发与商业化进程，拓展国内外市场份额，提升综合实力与核心竞争力，进而打开长期成长空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIWAN, Apr 20, 2026 - (ACN Newswire via SeaPRwire.com) - Positioned at the heart of East Asia and surrounded by the Pacific Ocean, Taiwan is emerging as one of Asia's most compelling wellness travel destinations, offering a rare combination of geological diversity, cultural depth, and accessible luxury.Welcome to Taiwan and its richly diverse island-wide hot spring experience.Among its most distinctive natural assets are its hot springs. Formed by volcanic activity and deep mountain geology, Taiwan's hot springs are rich in minerals known to support relaxation and overall wellbeing. For international travellers, these are not simply bathing destinations, but immersive experiences that combine nature, culture, and lifestyle.Taiwan is home to 19 officially recognised hot spring regions, each defined by unique mineral compositions and surrounding landscapes. From sulphur-rich volcanic springs to clear sodium bicarbonate waters, the diversity of spring types places Taiwan among the most varied hot spring destinations in the world.Two locations in particular have gained international attention. Tai'an Hot Spring in Miaoli and Jiaoxi Hot Spring in Yilan were both honoured with the 2025 "Top Ten Springs, Top Ten Beauties" Gold Award, one of Taiwan's highest recognitions in the hot spring sector.Nestled within forested mountains, Tai'an offers a tranquil retreat known for its smooth, skin-enhancing waters and strong connection to indigenous culture. Jiaoxi, located on a rare flatland hot spring zone, is widely recognised for its unique alkaline spring quality and convenient access to urban infrastructure, making it especially attractive for short-stay international visitors.Across the island, hot spring temperatures average around 40°C, providing a consistently comfortable and restorative experience. From northern mountain ranges to southern coastal regions, travellers can experience hot spring bathing throughout all four seasons, positioning Taiwan as a year-round wellness destination.Accessibility is another key advantage. Taiwan's integrated transport network, including High-Speed Rail, Taiwan Railways, and the Taiwan Tourist Shuttle, allows visitors to travel efficiently between cities and remote hot spring areas. This infrastructure enables flexible itineraries that cater to both short visits and extended stays.Accommodation options are equally diverse. International travellers can choose from premium five-star hot spring resorts, boutique design hotels, and locally operated guesthouses, offering a wide spectrum of experiences across different price points.In addition to its natural springs, Taiwan's culinary landscape enhances the overall travel experience. Each hot spring region is closely connected to local agricultural produce and regional cuisine. Visitors can enjoy mountain-grown ingredients, fresh coastal seafood, and Taiwan's globally recognised street food culture, creating a holistic journey that integrates wellness and gastronomy.Taiwan's 19 hot spring regions are distributed across the island:● Northern Taiwan: New Beitou,Shamao Mountain,Yangmingshan,Wulai,Jinshan-Wanli, Jiaosi, NeiwanJianshi● Central Taiwan: Taian, Guguan, Dakeng, Wuri, Beigang Rivers, Dongpu● Southern Taiwan: Guanzihling, Baolai, Sichong River, Eastern Taiwan: Antong, Rueisuei, JhihbenAs global travellers increasingly seek destinations that offer both physical relaxation and cultural depth, Taiwan is extending a clear invitation to Southeast Asia. With its combination of natural resources, modern infrastructure, and diverse experiences, Taiwan presents a compelling new choice for wellness-focused travel in the region.Travellers are encouraged to explore Taiwan at their own pace and experience the island's unique blend of warmth, nature, and hospitality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月20日 - (亚太商讯 via SeaPRwire.com) - 2026年4月16日至17日，“飞向深空”国际科创合作发展论坛在香港理工大学隆重举办，商业航天与低轨卫星领域备受资本市场瞩目。作为国内知名空间定位服务提供商，华大北斗携《低轨卫星通导一体化时代的芯片机遇与商业化前景》主题演讲亮相论坛，深度展望行业发展新机遇，充分彰显其在卫星导航芯片领域具备突出的技术优势与长期成长确定性。华大北斗董事长孙中亮：低轨卫星通导一体化迎来历史性机遇国家「十五五」规划明确提出，统筹建设卫星通信、导航、遥感系统，加快低轨卫星互联网组网，构建空天地一体、通导感算融合的综合服务体系。低轨卫星通导一体化服务，正从技术构想走向规模化应用。华大北斗董事长孙中亮在论坛演讲中指出，技术演进推动卫星通信与卫星导航深度融合，基于低轨星座的“无网实时通信+高精度定位”通导一体化服务，可构建全域覆盖、稳定可靠、低成本的时空信息服务体系，全面满足行业应用与大众消费的广泛多元需求。孙中亮亦在会中表示，中国拥有独具特色的通导一体化发展路径，可依托现有北斗短报文通信与高精度定位技术开展前期应用验证，为低轨通导融合开展技术预研与场景试验。当前低轨星座进入密集组网阶段，作为产业核心底座的芯片需求持续攀升，技术呈现集成化、小型化、低功耗发展趋势，卫星导航定位芯片企业既迎来历史性发展机遇，亦面临技术突破与生态构建的双重挑战。技术领先筑牢壁垒 全场景应用覆盖广阔市场 成长空间持续打开据悉，华大北斗已于2025年12月向港交所递交招股书。华大北斗长期专注于GNSS导航定位芯片、模组及相关解决方案的研发和应用，产品全方位赋能智能手机、可穿戴设备、物联网、交通管理、共享单车、智能驾驶和环境监测等多样化场景。招股书显示，公司已成长为全球第六、中国内地第二的GNSS空间定位服务提供商，并在双频高精度射频基带一体化芯片领域占据领先市场份额。公司坚持自主创新，持续推进产品迭代升级，完善产品矩阵，以高性能、高可靠、低功耗的芯片级解决方案，为通导一体化发展落地筑牢核心技术基础。随着卫星互联网建设提速、北斗应用规模化推进，卫星导航芯片行业进入高景气周期。华大北斗作为国内稀缺的高精度导航芯片龙头厂商，兼具技术壁垒与全场景落地能力，有望充分受益行业红利。华大北斗凭借在导航芯片领域的长期积累，正深度切入低轨通导一体化赛道，未来在商业航天与时空信息服务领域的增长动能充足，发展前景备受市场期待。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月17日 - (亚太商讯 via SeaPRwire.com) - 4月17日，国泰海通集团成员公司国泰君安国际控股有限公司（"国泰君安国际"，股份代号：1788.HK）作为联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人，成功助力长春长光辰芯微电子股份有限公司（"长光辰芯"，股份代号：3277.HK）在香港联交所主板上市。本次上市不仅标志着长光辰芯作为全球高性能CMOS图像传感器行业领导者迈入国际化资本市场，也填补了港股市场在该稀缺赛道的空白，为投资者提供了半导体产业成长红利的机遇，彰显了国泰海通在资源整合、跨境资本协同运作方面的突出优势以及精准赋能先进科技企业国际化发展的卓越能力。项目中，国泰君安国际高效推进执行、聆讯沟通、全球路演、定价配售等关键环节，助力长光辰芯顺利完成从递交申请至成功挂牌的全流程。本次发行最终定价为每股39.88港元，总发售股数达6,529.42万股，发行募集资金规模约26.04亿港元。国际配售和香港公开发售录得踊跃认购，国际配售认购倍数达22.7倍，香港公开发售认购倍数达1,138.2倍。此次发行获得了来自24家知名基石投资者的重仓加持，包括高瓴资本、博裕资本、CPE、景林资产、源码资本、雅润投资、UBS资管、惠理基金、未来资产、富国基金、易方达基金、华夏基金、工银理财等中外资长线基金。基石投资者合计认购股份约13.01亿港元，约占本次发售股份的50.0%，展现了市场对企业长期价值的充分认可和强劲信心，为股价的稳定提供了有力支撑。本次项目的顺利完成，得益于国泰海通充分发挥了公司境内外一体化协同优势。基于对半导体细分领域的前瞻洞察，凭借贯穿全程的专业服务与高效执行，国泰海通为长光辰芯提供了全方位的资本市场支持和服务，充分展现了其在服务前沿科技企业方面的深厚积累及专业能力。未来，国泰海通将积极发挥金融综合服务能力及境内外资源整合优势，持续赋能中国高新技术企业走向国际资本市场。关于长光辰芯长光辰芯是CMOS图像传感器（"CIS"）提供商，一直专注于CIS的研发，幷提供九大产品系列，广泛适用于工业成像、科学成像、专业影像和医疗成像等先进技术领域，产品在提高工业相机、科学相机、专业电影摄影机和其他成像设备的性能和成像质量方面发挥着至关重要的作用。根据弗若斯特沙利文的资料，就2024年的工业成像收入及科学成像收入而言，公司在全球 CIS公司中均排名第三，中国CIS公司中均排名第一，分别占全球市场份额的15.2%及16.3%。公司一直以技术创新为动力，专注于CMOS图像传感器，通过14年创新打造自主技术护城河，通过内部封装测试验证体系和战略扩展，已实现自主产业链的开发和整合，并与全球客户网络开展全面合作。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高质量、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"AAA"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的信息请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月17日 - (亚太商讯 via SeaPRwire.com) - 4月16日，专注于中国健康饮食行业的透云生物科技集团有限公司（"透云生物"，连同其附属公司统称"集团"；股份代号：1332.HK）欣然宣布，集团与深圳大学于2026年4月15日正式签订《科技成果转化战略合作协议》，双方将携手成立"深圳大学-透云生物莱茵衣藻联合研究所"，聚焦莱茵衣藻合成生物学领域的应用研究及成果转化，标志着集团在健康食品原料生产基础上向生物医药及合成生物领域迈出具有里程碑意义的关键一步。深圳大学是1983年成立的综合性大学，自1999年组建莱茵衣藻合成生物学课题组以来，先后发表相关研究论文400余篇，居全国之首。成功构建我国第一个药用单细胞真核微藻工程藻株库。并成功开发出基于莱茵衣藻模式平台的专利成果《一种稳定表达人源GLP-1RA的莱茵衣藻工程株及构建方法与应用（CN2025115510147），简称"衣藻格鲁肽"（Chlamyglutide）项目》等十余种成果。透云生物是全球唯一能够大批量发酵生产莱茵衣藻的科技型公司，年产4000吨莱茵衣藻粉的山西长治工厂已投产。双方约定形成长期战略合作伙伴关系，透云生物作为深圳大学莱茵衣藻研发成果的转化基地，共同打造世界一流的莱茵衣藻合成生物学工具平台及生物制造平台。根据协议，双方确定第一批启动的科技成果转化项目为深圳大学专利成果——衣藻格鲁肽。项目旨在利用经基因工程改造的莱茵衣藻工程藻株，稳定表达人源GLP-1受体激动剂，从而开发出一款以莱茵衣藻为生产平台的新型格鲁肽产品。根据合作分工，深圳大学将负责提供核心技术支持与专业人员培训，透云生物则承担中试验证、规模化生产、产品报批及市场推广等产业化全流程工作。双方亦将就具体的知识产权安排另行签署协议，以确保合作成果的合理分配与有效保护。此次战略合作将深圳大学在衣藻合成生物学领域的顶尖科研实力，与透云生物在莱茵衣藻规模化发酵生产方面的全球领先产业化能力深度融合，形成从基础研究、工程藻株构建到中试放大、规模化生产及市场推广的完整创新链条，实现科技成果从实验室到产业化的高效转化。莱茵衣藻作为国际公认的绿色模式生物，具有生长速度快、培养条件简单、可进行光合自养与发酵异养、且已获得美国食品药品监督管理局（FDA）"一般认为安全"（GRAS）认证及中国卫健委新食品原料批准等独特优势。以莱茵衣藻作为重组蛋白表达平台，相较于传统的大肠杆菌、酵母或哺乳动物细胞表达系统，在生产成本、安全性及可持续性方面均展现出显著的差异化竞争优势。若项目成功推进，有望为衣藻格鲁肽的生产开辟一条成本更低、更加绿色可持续的全新技术路径，并为未来口服生物药的开发提供创新平台支撑。透云生物董事会主席兼执行董事王亮先生表示："此次战略合作协议的签订，乃集团在合成生物学赛道上的重大战略布局。集团将依托‘深圳大学-透云生物莱茵衣藻联合研究所’的平台，持续推进莱茵衣藻在生物制药、功能性健康产品等高附加值领域的应用开发。集团将充分发挥自身在莱茵衣藻规模化发酵生产方面的全球独有优势，结合深圳大学在合成生物学领域的深厚学术积淀，加速推进衣藻格鲁肽等项目的产业化进程，力争早日实现产品落地。同时，集团亦将以此次合作为契机，持续探索莱茵衣藻平台在更多高价值生物活性分子生产中的应用潜力，为透云生物开辟更为广阔的增长空间，切实为股东创造长期价值。"关于透云生物科技集团有限公司透云生物科技集团有限公司（股份代号：1332.HK）主要从事莱茵衣藻产品业务、包装产品设计、研发、生产及销售业务。集团扎根传统包装业务超过三十载，在香港以及广东多地设有办公室及制造车间，目前为众多世界知名品牌提供专业包装设计及制造服务，拥有长期稳定的客户群。自2020年起，集团多元化发展业务范围至莱茵衣藻、微藻产品业务，并与山西省长治市潞城区人民政府合作建设全球首座莱茵衣藻工厂，以展开莱茵衣藻工业化量产。如欲查询更多资料，请浏览集团网站：https://touyunbiotech.com.hk/zh-hant/  Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

宾夕法尼亚州费城, 2026年4月16日 - (亚太商讯 via SeaPRwire.com) - 全球AI计算资源短缺迫使超大规模云服务商客户群以外的企业不得不长时间等待高性能GPU算力。Datavault AI Inc.（“Datavault AI”或“公司”） （纳斯达克代码：DVLT）是一家专注于数据变现、凭证认证、数字互动及现实世界资产（“RWA”）通证化技术的供应商，今日宣布其全新量子就绪型高性能计算（“HPC”）GPU网络的首批站点已在纽约和费城投入运营，整个48,000台GPU机群将于2026年第三季度开始正式投入商业运营。到2026年底，该集群将分布于美国100多个城市的1,000个城市微边缘新云站点。每个站点最多支持48个GPU，专为低延迟AI推理和HPC工作负载配置。根据当前Hopper和Blackwell级别的定价，这48,000块专用GPU的等效市场价值估计在14.4亿美元至19.2亿美元之间。¹该网络的建设独立于超大规模云服务商的供应链体系。目前，该供应链已吸纳了绝大多数Hopper和Blackwell级GPU产能，导致许多企业面临主要云服务商交货周期延长及按需供应受限的问题。² Available Infrastructure的SanQtum AI平台提供具备后量子密码学的网络安全、零信任、抗量子架构，该公司将其描述为“AI驱动、量子就绪的边缘计算”。Datavault AI的DataValue®、DataScore®及Information Data Exchange®（IDE®）平台直接运行于SanQtum安全防护的GPU基础设施之上，支持大规模的实时数据代币化、货币化及边缘AI工作负载。“GPU供应危机催生了双轨市场——超大规模云服务商坐拥充足产能，而企业却需在长达一年的等待名单中排队。Datavault AI Inc.（纳斯达克代码：DVLT）创始人兼首席执行官纳撒尼尔·T·布拉德利（Nathaniel T. Bradley）表示：“我们基于SanQtum AI网络安全边缘架构构建的量子就绪机群，为企业提供了一条通往安全AI计算、数据评分及代币化变现的途径，无需等待超大规模云服务商的配额分配。”计划到2026年7月初新增约30个城市部署点，4.8万块GPU的机群将于2026年第三季度全面投入商业运营，全国网络预计在2026年底前实现营收。该风冷、低功耗设计旨在突破曾限制超大规模扩展的电网和冷却液约束，使该集群成为企业安全AI计算能力的替代来源。当前市场中，少数超大规模云服务提供商已占据了绝大多数Hopper和Blackwell级别的计算能力。IDE®收益管理与品牌数据资产信息数据交换®（IDE®）将整合基于AI的收益管理与品牌数据资产评分机制，依据数据资产的质量、完整性及量子加密水平进行估值。IDE®、DataValue®和DataScore®将原生运行于SanQtum安全保障的机群之上，使Datavault AI的实时数据代币化与货币化能力得以在网络边缘而非集中式云区域中运行。来源¹ 根据已发布的 2026 年定价分析，当前 NVIDIA H100 80GB PCIe 和 SXM 的单张 GPU 价格约为 25,000 至 40,000 美元，而完整的 HGX H100 8-GPU 系统通常超过 350,000 美元。按每块GPU 30,000 至 40,000 美元的综合价格范围计算，48,000 块 GPU 的机群对应的市场价值相当于 14.4 亿至 19.2 亿美元。来源：IntuitionLabs，《NVIDIA AI GPU价格：H100（2.7万至4万美元）与H200（31.5万美元/8 GPU）成本指南》，2025年12月 - intuitionlabs.ai/articles/nvidia-ai-gpu-pricing-guide； Northflank，《NVIDIA H100 GPU 价格是多少？》，2026年 - northflank.com/blog/how-much-does-an-nvidia-h100-gpu-cost。² 超大规模云服务商的预订活动已消耗了英伟达大部分短期内的Hopper和Blackwell级产品配额，导致对于没有预先预留容量的团队而言，主要云平台上的H100按需供应“确实难以保障”。预计2026年超大规模云服务商的资本支出总额约为6600亿至6900亿美元，这将持续给GPU、内存和数据中心供应链带来压力。来源：Spheron Network，《2026年GPU短缺：当GPU售罄时如何确保AI计算资源》，2026年4月 - spheron.network/blog/gpu-shortage-2026； Introl，《2026年超大规模企业资本支出达6900亿美元》，2026年2月 - introl.com/blog/hyperscaler-capex-690-billion-microsoft-azure-power-bottleneck-2026。关于 Datavault AIDatavault AI™（纳斯达克股票代码：DVLT）在 Web 3.0 环境中引领人工智能驱动的数据体验、资产估值及变现领域。公司基于云的平台提供全面解决方案，其声学科学和数据科学部门致力于协作创新。Datavault AI的声学科学部门拥有WiSA®、ADIO®和Sumerian®等专利技术，以及业界首创的基础性空间和多通道无线高清音频传输技术，其知识产权涵盖音频时序、同步及多通道干扰消除等领域。数据科学部门则利用Web 3.0和高性能计算的强大能力，提供体验式数据感知、估值及安全变现的解决方案。Datavault AI的平台服务于多个行业，包括为体育与娱乐、活动与场馆、生物技术、教育、金融科技、房地产、医疗保健、能源等领域提供高性能计算软件授权。Information Data Exchange®通过将物理实体安全地关联至不可篡改的元数据，支持数字孪生以及姓名、形象和肖像的授权，从而促进具有诚信的负责任人工智能发展。该公司的技术套件完全可定制，提供基于人工智能和机器学习的自动化、第三方集成、详细分析与数据、营销自动化以及广告监测。公司总部位于宾夕法尼亚州费城。如需了解更多关于 Datavault AI 的信息，请访问 www.dvlt.ai 。前瞻性陈述本新闻稿包含关于 Datavault AI Inc.（“Datavault AI”、“本公司”、“我们”或“我们的”）及其所处行业的“前瞻性陈述”（定义见经修订的《1995 年私人证券诉讼改革法案》及其他证券法律），其中涉及风险和不确定性。在某些情况下，您可以通过以下词语识别前瞻性陈述，例如“可能”、“或许”、“将”、“应”、“应当”、“预期”、“计划”、“预料”、“能够”、“意图”、“目标”、 “预计”、“考虑”、“相信”、“估计”、“预测”、“潜在”、“目标”、“宗旨”、“寻求”、“可能”或“继续”等词语，或这些词语的否定形式，或其他涉及本公司预期、战略、计划或意图的类似术语或表述。未使用这些词语并不意味着相关陈述不属于前瞻性陈述。此类前瞻性陈述包括但不限于：关于未来事件的陈述；关于公司计划于2026年第三季度实现48,000个GPU的量子就绪高性能计算集群商业化；该集群的估算等值市场价值为14.4亿至19.2亿美元； 计划于2026年底前在美国100多个城市部署并启用1,000个城市微边缘新云站点，包括计划于2026年7月初前新增约30个城市的启用，以及该全国性网络计划于2026年底前实现创收；Available Infrastructure公司SanQtum AI平台的预期部署； 公司DataValue®、DataScore®及Information Data Exchange® (IDE®) 技术的预期功能与商业化进程，包括基于AI的收益管理、品牌数据资产评分、实时数据通证化及基于边缘的变现能力；公司提供网络边缘低延迟AI推理、高性能计算（HPC）能力、零信任安全及抗量子架构的能力； 该机群作为超大规模云服务商提供的 GPU 容量的替代方案的预期定位；以及本公司商业战略的预期运营、技术和商业成果，以及数字资产相关监管变化的预期方向和市场影响，必然基于某些估计和假设。尽管本公司及其管理层认为这些估计和假设是合理的，但它们本质上存在不确定性。谨此提醒读者，切勿过度依赖本文所载的这些及其他前瞻性陈述。由于存在各种风险和不确定性，包括但不限于以下方面，实际结果可能与这些前瞻性陈述所指明的结果存在重大差异：本公司能否按预期时间表开发、部署和扩展其GPU机群、微边缘Neocloud站点以及基于SanQtum的基础设施； 本公司能否确保获得充足的Hopper和Blackwell级或同等性能的GPU供应，并维持与Available Infrastructure的战略合作关系；与站点启用、许可、监管审批、电力供应、供应链状况及技术集成相关的风险；能否成功实施抗量子加密、零信任架构及AI驱动的收益管理； 公司能否从GPU网络和数据资产中产生预期的代币化费用、交易收入及其他变现收益；来自超大规模及其他AI和HPC算力提供商的竞争；市场对Datavault AI服务和产品的需求变化；经济、市场或监管环境的变化；与代币化资产、数字资产及跨境代币分发相关的不断演变的监管框架风险； 与技术开发及整合相关的风险；以及 Datavault AI 向美国证券交易委员会（SEC）提交的文件中更详细描述的其他风险和不确定性，包括截至 2025 年 12 月 31 日的 10-K 年度报告以及 Datavault AI 不时向 SEC 提交的其他文件，这些文件可在 SEC 网站 www.sec.gov 上查阅，且可能导致实际结果与预期存在差异。本新闻稿中的前瞻性陈述仅涉及陈述作出之日的事件。Datavault AI 无义务更新本新闻稿中的任何前瞻性陈述，以反映本新闻稿发布日之后的事件或情况，或反映新信息或意外事件的发生，除非法律另有要求。Datavault AI 可能无法实际实现其前瞻性陈述中披露的计划、意图或预期，您不应过度依赖此类前瞻性陈述。Datavault AI 的前瞻性陈述未反映其未来可能进行的任何收购、合并、处置、合资或投资的潜在影响。行业与市场数据在本新闻稿中，我们引用了关于本公司产品市场的信息和统计数据。其中部分信息和统计数据来源于各类独立第三方来源，包括独立行业出版物、市场研究公司的报告及其他独立来源。本新闻稿中包含的某些数据及其他信息亦基于管理层的估算和计算，这些估算和计算源于我们对内部调查及独立来源的审查和解读。关于我们所处行业、以及我们在这些行业中的市场地位和市场份额的数据，本质上存在不精确性，且受制于我们无法控制的重大商业、经济和竞争不确定性，但我们认为这些数据总体上反映了该行业的规模、地位及市场份额。尽管我们认为此类信息可靠，但我们并未对任何第三方信息进行独立核实。虽然我们相信公司的内部研究和估算可靠，但此类研究和估算尚未经过任何独立来源的验证。此外，由于多种因素的影响，关于本公司及所处行业未来表现的假设和估计必然存在高度的不确定性和风险。这些及其他因素可能导致我们的未来表现与假设和估计存在重大差异。因此，您应知悉，本新闻稿中包含的市场、排名及其他类似行业数据，以及基于该数据的估计和判断，可能并不可靠。商标、商号、服务标记及版权我们拥有或有权使用各种商标、商号、服务标记和版权，这些均受适用知识产权法律的保护。本新闻稿还包含其他公司的商标、商号、服务标记和版权，据我们所知，这些均为其各自所有者的财产。仅为方便起见，本新闻稿中提及的某些商标、商号、服务标记和版权可能未标注 ©、® 和 ™ 符号，但此类表述绝不意味着我们将不会在适用法律允许的最大范围内，主张我们或相关许可方对这些商标、商号、服务标记和版权所享有的权利。我们使用或展示其他方的商标、商号、服务标记或版权，并非意在暗示，且此类使用或展示不应被解释为暗示与这些其他方存在关系，或暗示我们获得了这些其他方的认可或赞助。媒体联系marketing@dvlt.ai  投资者联系Edward Barger投资者关系副总裁ebarger@dvlt.ai | ir@dvlt.ai 来源：Datavault AI Inc Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA, Apr 16, 2026 - (ACN Newswire via SeaPRwire.com) - The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026.The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each site supports up to 48 GPUs configured for low-latency AI inference and HPC workloads. Equivalent market value of the dedicated 48,000-GPU capacity is estimated at $1.44 billion to $1.92 billion based on current Hopper- and Blackwell-class pricing.¹The network is built outside the hyperscaler supply chain, which has absorbed the majority of current Hopper- and Blackwell-class GPU capacity and left many enterprises facing extended lead times and limited on-demand availability from major cloud providers.² Available Infrastructure's SanQtum AI platform provides cyber-secure, zero-trust, quantum-resistant architecture with post-quantum cryptography, which Available Infrastructure describes as "AI-powered, quantum-ready edge computing." Datavault AI's DataValue®, DataScore®, and Information Data Exchange® (IDE®) platform runs directly on the SanQtum-secured GPU infrastructure, powering real-time data tokenization, monetization, and edge AI workloads at scale."The GPU supply crisis has created a two-tier market - hyperscalers with capacity and enterprises waiting in a year-long queue. Our quantum-ready fleet, built on SanQtum AI's cyber-secure edge architecture, gives enterprises a path to secure AI compute, data scoring, and tokenized monetization without waiting for hyperscaler allocations," said Nathaniel T. Bradley, Founder & CEO, Datavault AI Inc. (NASDAQ:DVLT).Approximately 30 additional city activations are targeted by early July 2026, with full commercial availability of the 48,000-GPU fleet beginning Q3 2026 and the nationwide network scheduled to be revenue-generating by the end of 2026. The air-cooled, lower-power design is engineered to bypass the power-grid and coolant constraints that have limited hyperscale expansion, positioning the fleet as an alternative source of secure enterprise AI compute capacity in a market in which a small number of hyperscale cloud providers have absorbed the majority of current Hopper- and Blackwell-class capacity.IDE® Yield Management and Branded Data AssetsThe Information Data Exchange® (IDE®) will incorporate AI-powered yield management and branded data asset scoring, with data assets valued for quality, completeness, and quantum encryption. IDE®, DataValue®, and DataScore® will run natively on the SanQtum-secured fleet, enabling Datavault AI's real-time data tokenization and monetization capabilities to operate at the network edge rather than in centralized cloud regions.Sources¹ Current NVIDIA H100 80GB PCIe and SXM pricing ranges from approximately $25,000 to $40,000 per GPU, and full HGX H100 8-GPU systems routinely exceed $350,000, according to published 2026 pricing analyses. At a blended $30,000 to $40,000 per-GPU range, a 48,000-GPU fleet corresponds to an equivalent market value of $1.44 billion to $1.92 billion. Sources: IntuitionLabs, "NVIDIA AI GPU Prices: H100 ($27K-$40K) & H200 ($315K/8-GPU) Cost Guide," December 2025 - intuitionlabs.ai/articles/nvidia-ai-gpu-pricing-guide; Northflank, "How much does an NVIDIA H100 GPU cost?" 2026 - northflank.com/blog/how-much-does-an-nvidia-h100-gpu-cost.² Hyperscaler reservation activity has consumed the majority of NVIDIA's near-term Hopper- and Blackwell-class allocation, leaving on-demand H100 availability on major cloud platforms "genuinely unreliable" for teams without pre-existing reserved capacity. Combined 2026 hyperscaler capital expenditures are projected at approximately $660-690 billion, driving sustained pressure on GPU, memory, and data-center supply chains. Sources: Spheron Network, "GPU Shortage 2026: How to Secure AI Compute When GPUs Are Sold Out," April 2026 - spheron.network/blog/gpu-shortage-2026; Introl, "Hyperscaler CapEx Hits $690B in 2026," February 2026 - introl.com/blog/hyperscaler-capex-690-billion-microsoft-azure-power-bottleneck-2026.About Datavault AIDatavault AI™ (NASDAQ:DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization.Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring.The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.Forward-Looking StatementsThis press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. ("Datavault AI," the "Company," "us," "our," or "we") and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the anticipated Q3 2026 commercial availability of the Company's 48,000-GPU quantum-ready high-performance computing fleet; the estimated equivalent market value of the fleet of $1.44 billion to $1.92 billion; the planned deployment and activation of 1,000 urban micro-edge neocloud sites across more than 100 U.S. cities by the end of 2026, including the approximately 30 additional city activations targeted by early July 2026 and the scheduled revenue-generating status of the nationwide network by year-end 2026; the expected deployment of Available Infrastructure's SanQtum AI platform; the anticipated capabilities and commercialization of the Company's DataValue®, DataScore®, and Information Data Exchange® (IDE®) technologies, including AI-powered yield management, branded data asset scoring, real-time data tokenization, and edge-based monetization; the Company's ability to deliver low-latency AI inference, HPC capacity, zero-trust security, and quantum-resistant architecture at the network edge; the expected positioning of the fleet as an alternative to hyperscaler-supplied GPU capacity; and the expected operational, technical, and commercial outcomes of the Company's commercial strategy, and the projected direction and market impacts of regulatory changes with respect to digital assets, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain.Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein.Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the Company's ability to develop, deploy, and scale its GPU fleet, micro-edge neocloud sites, and SanQtum-based infrastructure on the anticipated timelines; the Company's ability to secure sufficient Hopper- and Blackwell-class or equivalent GPU supply and to maintain its strategic relationship with Available Infrastructure; risks relating to site activation, permitting, regulatory approvals, power availability, supply chain conditions, and technological integration; the successful implementation of quantum-resistant encryption, zero-trust architecture, and AI-powered yield management; the Company's ability to generate anticipated tokenization fees, transaction revenues, and other monetization from the GPU network and data assets; competition from hyperscale and other providers of AI and HPC capacity; changes in market demand for Datavault AI's services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets, digital assets, and cross-border token distribution; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC's website at www.sec.gov, and could cause actual results to vary from expectations.The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make.Industry and Market DataWithin this press release, we reference information and statistics regarding the market for our products. We have obtained some of this information and statistics from various independent third-party sources, including independent industry publications, reports by market research firms and other independent sources. Some data and other information contained in this press release are also based on management's estimates and calculations, which are derived from our review and interpretation of internal surveys and independent sources. Data regarding the industries in which we compete and our market position and market share within these industries are inherently imprecise and are subject to significant business, economic and competitive uncertainties beyond our control, but we believe they generally indicate size, position and market share within this industry. While we believe such information is reliable, we have not independently verified any third-party information. While we believe our internal company research and estimates are reliable, such research and estimates have not been verified by any independent source. In addition, assumptions and estimates of our and our industries' future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates. As a result, you should be aware that market, ranking and other similar industry data included in this press release, and estimates and beliefs based on that data, may not be reliable.Trademarks, Trade Names, Service Marks and CopyrightsWe own or have rights to use various trademarks, tradenames, service marks and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the ©, ®, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties' trademarks, tradenames, service marks or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.Media Contactmarketing@dvlt.aiInvestor ContactEdward BargerVP, Investor Relationsebarger@dvlt.ai | ir@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 16, 2026 - (ACN Newswire via SeaPRwire.com) - InnoEX, jointly organised by the Innovation, Technology and Industry Bureau (ITIB) of the Hong Kong SAR Government and the Hong Kong Trade Development Council (HKTDC), and the HKTDC’s Hong Kong Electronics Fair (Spring Edition) (EFSE), both concluded today. The four-day exhibitions were a resounding success, attracting over 88,000 buyers from 155 countries and regions for connection building and business matching. Buyers from outside Hong Kong mainly came from the Chinese Mainland, Japan, India, the United States, and Korea, among others.Jenny Koo, Deputy Executive Director of the HKTDC, said: "InnoEX and EFSE bring together elites from the global innovation, technology, and electronics industries, and leverage Hong Kong's unique advantage of connecting the Chinese Mainland and the world. The HKTDC provides a crucial platform connecting global innovation and technology by assisting Chinese Mainland enterprises in expanding overseas and seizing global business opportunities and also offering global enterprises a springboard to enter the Asian and Chinese Mainland markets. The HKTDC helps enterprises from various regions master cutting-edge technologies, promotes in-depth cross-industry and cross-sectoral exchanges and application transformation, and also promotes Hong Kong's development as an international innovation and technology hub."Both exhibitions align with China’s 15th Five-Year Plan and the innovation and technology policies in the Hong Kong Government’s latest Budget, which focus on cutting-edge technologies and market applications driven by AI. The newly launched RoboPark brought together technology companies from Hong Kong, the Chinese Mainland and overseas. RoboPark featured over 100 robots in a variety of application scenarios. Among the exhibitors at the RoboPark, UBTECH is the world’s first humanoid robot company listed in Hong Kong. As one of the top five global humanoid robot vendors by sales[1], UBTECH engaged with potential buyers from the Chinese Mainland, the United States, Europe and Southeast Asia during the fair. The company reported that its participation delivered results well beyond expectations, underscoring the exhibition’s strong international reach.Global buyers gather and enterprises expand into overseas markets via exhibitionsInnoEX focused on five key areas: AI+, Robotics, the Low-altitude Economy, Property Technology and Retail Technology, presenting a comprehensive showcase of innovation and cutting‑edge technology solutions. The fair brought together exhibitors from 21 countries and regions. Both the UK Pavilion and the Macao Pavilion welcomed the strong turnout of high‑quality buyers, with exhibitors from the Macao Pavilion alone holding more than 280 business meetings during the first three days of the exhibition.In addition, the exhibition featured participation from universities, research institutes and leading technology enterprises, including Huawei, China Mobile Hong Kong, HKT and Lenovo. Beyond exhibiting, Huawei organised Huawei Hong Kong Tech Week 2026 concurrently with InnoEX. Through 12 themed events and industry‑specific forums, Huawei explored innovative applications and real‑world practices of Artificial Intelligence+ across various sectors, generating strong synergy with InnoEX and further enriching the exhibition’s thought‑leadership programme.The Chinese Mainland pavilions comprised from 17 provinces and municipalities. Among them, Zhongguancun Beijing Hong Kong-Macao Youth Innovation Center which has been bringing delegations to the fair since its inaugural edition, said that the 10 high‑quality technology enterprises in this year’s delegation span a wide range of frontier technology sectors, including artificial intelligence, intelligent robotics, the low altitude economy and application‑specific chips. On the first day of the exhibition alone, the delegation attracted strong interest from relevant institutions and enterprises from Brazil, Germany, India, Japan, Malaysia, South Korea and the Middle East.EFSE showcased smart living electronics and new products attracting buyers' attentionThe EFSE presented three major areas, including Smart Home & Solutions, Health Tech & Gadgets, and Pet Intelligence, with around 60 products being launched for the first time. Among them, local company HelloBaby, which specialises in the research, development and sales of baby monitor products, showcased its latest product at the fair. Qin Zhihui, Sales Director at HelloBaby, said: “The exhibition is highly international in character, and we participate every year. Our buyers mainly come from Japan, Korea, Singapore and other Asian markets.”Buyers noted that EFSE is a strong brand‑focused platform, enabling companies to connect successfully with Chinese Mainland and global markets through Hong Kong’s international platform. Carmate Electronics Pty Ltd, an Australian manufacturer of automotive electronics, said it had successfully engaged with a number of high‑quality buyers from markets, including Brazil, Mexico, Belgium and Indonesia, through EFSE. The company recorded potential transactions of around US$200,000 on the first day and expects follow‑up orders to reach US$400,000 to US$500,000. Michael Lin, General Manager of the company, noted that amid heightened China‑US tensions, Hong Kong’s unique role as an international platform has positioned the city as an important bridge between overseas and Chinese Mainland enterprises, generating valuable business opportunities. He described the exhibition as highly fruitful and confirmed the company’s participation again next year.In addition to one‑stop sourcing, buyers also gained valuable insights into industry trends. Pari Jazz, a buyer from Germany‑based P.J Global Way Management Ltd, said that the exhibition not only enabled her to place orders, but also helped her stay abreast of the latest market trends and technological developments. Overall, she found the experience highly rewarding. During the fair, she arranged around 12 business meetings, engaging with exhibitors from Hong Kong, the Chinese Mainland and Denmark, meeting approximately 10 to 13 contacts in total, and identifying two to three potential partners with good prospects for collaboration.Over 100 events with 260+ speakers decoding new industry trendsInnoEX and EFSE invited many well-known technology companies, industry experts and scholars to share the latest industry trends, technological innovations and practical experiences with buyers, promoting in-depth exchange and cooperation. This year, more than 260 speakers shared their insights across the fair’s five major thematic areas.In the area of AI+, the Hong Kong Computer Society co-organised the session ‘From +AI to AI+: Enhancing Workplace Performance’ during the exhibition, where representatives from HKT Limited, Lenovo and CLP joined other industry leaders to exchange insights and foster greater innovation collaboration. InnoEX, for the first time, co-organised the ‘Low-altitude Economy Development Conference’ with the Working Group on Developing Low-altitude Economy and the Greater Bay Area Low-altitude Economy Alliance. Distinguished guests included Michael Wong, Deputy Financial Secretary of the HKSAR; Liu Chun-san, JP, Under Secretary for Transport and Logistics, HKSAR Government; Bakhtiyar Mukhametkaliyev, Vice Minister of Artificial Intelligence and Digital Development of Kazakhstan; and Professor Zhang Qingxin of the Liaoning General Aviation Academy, who shared insights on the development opportunities of the low-altitude economy across Hong Kong, the Chinese Mainland, ASEAN and Central Asia.Another highlight was the thematic seminar ‘Embodied AI in Robotics: The Dawn of Autonomy,’ which explored the rise of embodied artificial intelligence in robotics, marking a new era where autonomous systems are capable of independent decision-making and executing complex tasks. Distinguished speakers included Prof Xuguang Lan from the School of Artificial Intelligence at Xi’an Jiaotong University and Kristine Mo, Vice President of Global Market and Ecosystem at AI² Robotics,  who shared how AI-driven robotics are transforming industries such as education, entertainment and services, while delving into technological breakthroughs, ethical considerations and future applications.Some 80% of respondents have explored or adopted generative AI technologiesTo further understand the development trends of the innovation and technology as well as the electronics industry, an independent institution was appointed to conduct surveys during the fairs, interviewing 347 exhibitors and buyers at InnoEX and 648 exhibitors and buyers at EFSE. Key findings are as follows:InnoEX and EFSE81% of respondents expressed interest in expanding into emerging markets, including Europe, ASEAN, the Chinese Mainland, and Latin America.78% of respondents indicated that their companies have already explored or adopted generative AI technologies.InnoEXIn terms of applications of generative AI, 42% of respondents said they have applied or are planning to apply it to sales and customer communications, 40% to data analysis and reporting, while 39% plan to deploy it in product design and research and development.EFSE59% of respondents expect their overall sales revenue to increase in the next one to two years.33% of respondents believe that, compared with traditional electronic products and appliances, consumers are willing to pay a premium of 11% to 20% for products that support smart home or artificial intelligence applications.[1]Source: Omdia Market Radar: General-purpose Embodied Intelligent Robots, 2026, published on 8 January 2026.Photo download: https://bit.ly/3Qt7Fd3InnoEX, jointly organised by the Innovation, Technology and Industry Bureau (ITIB) of the HKSAR Government and the Hong Kong Trade Development Council (HKTDC), and the HKTDC’s Hong Kong Electronics Fair (Spring Edition) (EFSE), successfully concluded today, attracting over 88,000 buyers from 155 countries and regions for connection building and business matchingThe newly launched RoboPark brings together technology companies from Hong Kong, the Chinese Mainland and overseas, featuring over 100 robots and hosting approximately 40 eventsInnoEX brings together exhibitors from 21 countries and regions, including 18 Chinese Mainland delegations from 17 provinces and cities. The photo is Guangdong delegationInnoEX partnered with the Working Group on Developing Low-altitude Economy for the first time to set up a Low‑Altitude Economy Zone, showcasing low altitude technology applications and promoting industry cooperationInnoEX and EFSE invited many well-known technology companies, industry experts, and scholars to share the latest industry trends. More than 260 speakers shared their insights across the fair’s five major thematic areas. The photo is the Hong Kong Computer Society co-organised the session ‘From +AI to AI+: Enhancing Workplace Performance’ during the exhibitionMany leading technology companies made a strong presence at InnoEX, engaging in in‑depth exchanges with global buyers and industry partners.During the exhibition, Dean Ward, representative of UK Pavilion exhibitor PropSmarts, successfully concluded a partnership and licensed distribution agreement with a geographic information system (GIS) software companyThe Retail 4.0: Reshaping Consumer Experiences seminar invited many industry leaders, including representatives from the Hong Kong Retail Management Association, DECATHLON Hong Kong, Tradelink Electronic Commerce Limited, Adyen, Visa, and Tencent Cloud, to discuss the innovative trends and future direction of the retail industryInnoEX, for the first time, co-organised the “Low-altitude Economy Development Conference” with the Working Group on Developing Low-altitude Economy and the Greater Bay Area Low-altitude Economy Alliance. Distinguished guests included Michael Wong, Deputy Financial Secretary of the HKSAR and Bakhtiyar Mukhametkaliyev, Vice Minister of Artificial Intelligence and Digital Development of Kazakhstan, who shared insights on the development opportunities of the low-altitude economyHong Kong Electronics Fair (Spring Edition) (EFSE) features an Immersive Experience Zone, where local innovation and technology companies present immersive interactive games using VR, AR and XR technologies.WebsitesInnoEX: innoex.hktdc.com/enHong Kong Electronics Fair (Spring Edition): hkelectronicsfairse.hktdc.com/enMedia enquiriesYuan Tung Financial Relations:Salina Cheng Tel: (852) 3428 2362 Email: salcheng@yuantung.com.hkTiffany Leung Tel: (852) 3428 2361 Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Stanley So Tel: (852) 2584 4049 Email: stanley.hp.so@hktdc.orgNavin Law Tel: (852) 2584 4525 Email: navin.cm.law@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

General Wayne Eyre to Strengthen Focus Graphite's Engagement with Defence and Allied Partners Across Critical Supply ChainsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - April 16, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the appointment of General (Retired) Wayne Eyre, former Chief of the Defence Staff ("CDS") of the Canadian Armed Forces ("CAF"), to its Advisory Board.This appointment comes at a time when global security priorities are increasingly shaped by access to secure, reliable supply chains for critical minerals essential to defence systems, energy storage, and advanced technologies.General Eyre served more than forty (40) years in the CAF, culminating as CDS from 2021 to 2024, where he led Canada's military through a period of rapidly evolving geopolitical and security challenges. Throughout his career, he commanded at all levels, including the Canadian Army and Military Personnel Command. He served on numerous overseas missions including in the Former Yugoslavia, Afghanistan, and as Deputy Commander of United Nations Command in Korea, where he was the most senior Canadian officer ever permanently stationed in the Asia Pacific region.He brings extensive operational and institutional experience across U.S. and allied defence systems, including completion of the U.S. Army Special Forces Qualification Course, the U.S. Marine Corps Command and Staff College, the U.S. Marine Corps School of Advanced Warfighting, and the U.S. Army War College. General Eyre holds a Bachelor of Science and three master's degrees in Military Studies, Operational Studies, and Strategic Studies.His decorations include the Commander of the Order of Military Merit, the Meritorious Service Cross, and multiple international honours from allied nations, recognizing his leadership and service across the globe. He is currently a Visiting Professor and Senior Fellow at the University of Ottawa's Graduate School of Public and International Affairs, and continues to advise on global security, defence transformation, and strategic leadership.In his role with Focus, General Eyre will provide strategic guidance on defence-related applications of graphite, support engagement with allied and NATO-aligned partners, and advise on positioning the Company within evolving North American and allied critical minerals frameworks."Our high-quality material and thermal purification process lends itself to defence and advanced systems," said Dean Hanisch, CEO of Focus Graphite. "General Eyre's leadership at the highest levels of the Canadian Armed Forces, combined with his deep experience across NATO and allied operations, brings critical insight to our strategy. His perspective will help position Focus Graphite as a trusted supplier supporting defence, energy, and advanced material systems across allied nations.""The character of modern security is changing, with supply chains becoming as critical as the systems they support," said General Wayne Eyre. "Materials like graphite are foundational to energy storage, advanced technologies, and defence readiness. Focus Graphite is well positioned to contribute to strengthening secure, sovereign supply chains, and I look forward to supporting the Company as it advances its role within Canada and across NATO partners."This appointment further strengthens Focus Graphite's positioning at the intersection of critical minerals, defence readiness, and advanced materials development. The Company continues to advance its Lac Knife and Lac Tetepisca projects, alongside downstream processing initiatives, to support a secure and resilient North American supply chain.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures an eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact:Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated contributions of General Wayne Eyre in his role as an advisor to the Company; the Company's ability to leverage his experience to support engagement with defence stakeholders, NATO-aligned partners, and allied supply chain initiatives; the growing importance of secure, North American sources of graphite for defence, energy storage, and advanced technologies; and the Company's plans and objectives for advancing its Lac Knife and Lac Tétépisca projects, downstream processing capabilities, and broader critical minerals strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 16, 2026 - (ACN Newswire via SeaPRwire.com) - Sigenergy Technology Co., Ltd. (“Sigenergy” or “the company” Stock Code: 06656.HK) officially commenced trading on the Main Board of the Hong Kong Stock Exchange (HKEX) today. As the first “AI + All-in-One PV Storage” company to list on the exchange, Sigenergy has set a new record for the fastest IPO by a Chinese enterprise.The stock showed strong momentum on its debut, opening at HK$ 581, representing almost an 80% increase over the offer price. Market cap exceeded HK$140 billion. Based on the offer price of HK$324.20 per share, the company raised over HK$4.4 billion in its IPO. If the over-allotment option (greenshoe) is exercised in full, the total proceeds will reach HK$5.06 billion.A Milestone for the Company, the Beginning for a New ChapterFounded only 3 years and 11 months ago, Sigenergy’s rapid path to listing reflects its focus on defining new industry standards rather than following short-term market trends. The IPO attracted a prestigious group of cornerstone investors, highlighting the company’s strategic value in the 2026 Hong Kong market.At the listing ceremony, Mr. Xu Yingtong, Founder and CEO of Sigenergy, together with Mr. Zhang Xianmiao, President of Sigenergy, witnessed this pivotal milestone in the company’s journey.Mr. Xu Yingtong stated: “Listing marks a new beginning for us. Guided by our ‘AI in All’ mission, we are doubling down on energy storage and accelerating R&D to fortify our competitive edge. Our goal is to ensure that AI translates into tangible value for our customers. As we advance our global expansion and refine our international network, we are proud to share the story of ‘China’s Intelligent Manufacturing’ in the renewable energy sector. We promise to uphold the highest standards of operational excellence, rewarding your trust with exceptional results and building a legacy as a transparent, reliable, and socially responsible enterprise.” Sigenergy’s cornerstone investors include world-class sovereign wealth funds and asset managers such as Temasek, Goldman Sachs Asset Management, UBS Asset Management, and BNP Paribas Asset Management. Other notable participants include Hillhouse, CPE, Boyu Capital, Gaoyi Asset Management, and Greenwoods Asset Management, alongside insurance and specialized funds like CPIC, ORIX, and Walden International.This diverse group of high-caliber investors signals a strong market consensus: Sigenergy is recognized as a unique player in the “AI + All-in-One PV Storage” sector, underpinned by proprietary technology, high entry barriers, and predictable growth. Beyond a mere endorsement of the company, this capital influx confirms the market’s conviction that “AI-native” architecture is the definitive standard for next-generation energy storage.Market confidence is supported by Sigenergy’s rapid scale-up. According to the prospectus, the company’s revenue grew from RMB 58.30 million in 2023 to RMB 9.00 billion in 2025, increased 154.4 times in two years. During this period, gross margins expanded from 31.3% to 50.1%, with an adjusted net margin reaching 35.9%. These figures validate the commercial viability of Sigenergy’s “AI-native” technology path.Differentiation Through “AI-Native” TechnologyUnlike traditional “hardware-first, AI-enabled” peers, the company established a more thorough “AI-native” path by integrating artificial intelligence across product design, manufacturing, and business models, the company has achieved a system that is inherently intelligent and capable of continuous evolution.Its flagship product, SigenStor, is a five-in-one system that combines an inverter, EV DC charging module, and battery pack into a modular, stackable unit which achieves a deep integration of power electronics, cloud and AI technologies, enhances product performance while delivering a more convenient user experience.The actual value of system’s “AI-native” capabilities is particularly effective in markets with dynamic electricity pricing. Facing fluctuations on an hourly or even minute-by-minute basis, traditional “charge at low, use at high” strategies based on fixed rules are no longer sufficient. By analyzing real-time prices, weather forecasts, and consumer habits, the system optimizes energy scheduling. In the Swedish market, SigenStor helped users reduce electricity costs by an average of 70.3%, showing the effective translation from AI technology into tangible financial benefits.Sigenergy continuously strengthens its competitive edge through a “Data-Intelligence” closed-loop. As global install base grows, the system leverages real-world operational data to undergo autonomous learning and optimization. This evolution directly translates into superior economic returns for users, which in turn fosters brand loyalty and higher retention. This data-driven cycle creates a powerful network effect, establishing a formidable, long-term barrier to entry in the Energy AI sector.Since its launch, SigenStor has established a strong global presence through its unique value proposition. According to Frost & Sullivan, Sigenergy has become the world No.1 provider of stackable distributed PV and storage all-in-one solutions in 2024, securing a 28.6% market share. Further data from SunWiz confirms that in 2025, the company ranked first in the under-1000kWh segment across Australia, Ireland, and South Africa, while maintaining a top-tier position in the UK, Sweden, and the Netherlands. This deep penetration into high-value markets has delivered significant commercial returns and reinforced Sigenergy’s brand equity. As the company expands into the Asia-Pacific and Latin American regions, its growth trajectory remains robust.To support the trajectory, the company has built a robust manufacturing footprint with production bases in Lingang and Jinqiao, Shanghai, as well as Nantong, Jiangsu. By the end of 2025, the company achieved an annual design capacity of nearly 360,000 inverters and over 5.6 GWh of energy storage batteries. This infrastructure provides a stable foundation for the company’s ongoing global expansion.The successful HKEX listing marks a significant milestone in Sigenergy’s commitment to innovation and recognizes its substantial growth potential. Entering this new chapter, and with the support of premier institutional investors, Sigenergy will focus on optimizing resource integration and accelerating its global ‘AI + Energy Storage’ strategy. By solidifying its technological leadership and market presence, the company aims to build a sustainable foundation for long-term value creation.For inquiries, please contact:EVER BLOOM (HK) COMMUNICATIONS CONSULTANTS GROUP LIMITEDMs. Claire ZhangTel: (852)3468 8171Email: project_alps.list@everbloom.com.cn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北, 2026年4月16日 - (亚太商讯 via SeaPRwire.com) - OBI Pharma, Inc.（TPEx:4174.TWO）今日宣布将出席 AACR 2026 年会，并通过十篇海报展示其 GlycOBI® 平台的变革性潜力。传统 ADC 常因随机偶联而受到限制，导致药物与抗体比值（DAR）不均一、稳定性不足以及治疗窗口狭窄。相比之下，OBI 的位点特异性糖链技术可实现高度均一的 DAR，从而带来更优的 PK/PD 特征，并降低脱靶毒性，这一点已在 OBI 的主要项目 OBI-902 和 OBI-904 中得到验证。我们正通过新一代双特异性（OBI-201）以及双特异性双载荷（OBI-221）ADC 推动精准肿瘤学的进一步发展。这些“以生物学驱动”的分子旨在克服肿瘤异质性和多药耐药性——这是当前癌症治疗中的关键挑战。通过结合 GlycOBI® 与 GlycOBI DUO® 平台，OBI 正在开发具有创新性和差异化的疗法，以满足难治性实体瘤患者尚未被满足的医疗需求。此外，OBI 强大的 ADC 偶联平台已被证明能够稳定实现产品质量与可扩展性，同时支持向下一代治疗模式拓展，包括降解剂-抗体偶联物（DAC）。这些数据将于 2026 年 4 月 17 日至 22 日在美国加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）年会上展示。“在 OBI，我们致力于打造更优质的 ADC，”OBI Pharma 首席科学官陈雅琪博士表示。“我们的目标是提供不仅能够更有效、更精准靶向肿瘤，同时还能减少副作用的疗法，为患者带来具有潜在改变生命意义的治疗选择。”2026年4月20日（星期一）（上午9:00 - 12:00）标题：通过 OBI-902 克服耐药性：下一代 TROP2 ADC 的临床前评估1 作者：Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen。OBI Pharma, Inc，台湾台北 会议主题：PO. ET07.01 - 定量药理学与转化建模 地点：海报区 17 海报编号：6 摘要编号：1818标题：OBI-904，一种靶向 Nectin-4 的下一代 Exatecan ADC，展现出增强的细胞毒性并克服 Enfortumab Vedotin 耐药性2作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc，台湾台北会议主题：PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：26 摘要编号：1729标题：OBI-904，一种基于糖链的位点特异性靶向 Nectin-4 的 ADC，在非临床研究中展现出强效且持久的抗肿瘤活性，并具有改进的 PK 特征及克服 EV 耐药性的能力3 作者：Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题：PO.ET07.01 - 定量药理学与转化建模 地点：海报区 17 海报编号：7 摘要编号：1819标题：具有双载荷的 MET/HER3 抗体药物偶联物：一种消除肿瘤逃逸机制的双靶点策略5 作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.CL.0705 - 靶向抗原疗法与免疫 地点：海报区 49 海报编号：17 摘要编号：2665标题：引导-效应 bsADC：通过协同内吞作用提升载荷递送效率6作者：Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：27 摘要编号：1730标题：亲水性增强的连接子技术实现位点特异性的降解剂-抗体偶联物，具有改进的稳定性和增强的活性7 作者：Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台湾台北会议主题：PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：28 摘要编号：1731标题：基于细胞的载荷释放揭示双载荷 ADC 中设计、位点及细胞依赖的比例变化8 作者：Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.CH01.06 - 抗体、抗体药物偶联物与核酸 地点：海报区 38 海报编号：5 摘要编号：23972026 年 4 月 20 日（星期一）（下午 2:00 - 5:00）标题：TROP2 上调及其与 HER2 的相互作用介导曲妥珠单抗耐药性4 作者：Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题：PO.ET03.06 - 药物耐药性 1：抗体与 ADC 地点：海报区 12 海报编号：18 摘要编号：29722026 年 4 月 21 日（星期二）（上午 9:00 - 12:00）标题：基于糖链的位点特异性 ADC 通过改进的载荷递送和免疫激活实现持续的肿瘤控制9 作者：Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi。OBI Pharma, Inc., 台湾台北会议主题： PO.IM02.04 - 癌症中的适应性免疫 地点：海报区 6 海报编号：2 摘要编号：4234标题：通过新一代位点特异性糖链偶联与双载荷灵活性推进 ADC 治疗的发展10 作者：Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台湾台北会议主题： PO.ET02.03 - 抗体药物偶联物与连接子工程 3 地点：海报区 12 海报编号：1 摘要编号：4423电子海报将于 4 月 17 日太平洋时间中午 12:00 起在 AACR 虚拟会议平台上线供浏览，同时也将于 4 月 18 日起在 OBI Pharma 官网（www.obipharma.com）上线。1 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/5403关于 OBI PharmaOBI Pharma 是一家处于临床阶段的全球肿瘤学公司，成立于 2002 年，总部位于台湾。公司与其子公司 OBI Pharma USA, Inc. 致力于开发创新癌症疗法，为具有紧迫医疗需求的患者提供新的治疗选择。OBI 的研究重点是新型抗体药物偶联物（ADC）。通过其专有的下一代偶联技术平台 Obrion™，OBI 建立了多样化的 ADC 设计模式。该平台整合了专有的偶联和连接子技术，包括 GlycOBI®、GlycOBI DUO®、EndoSymeOBI®、HYPrOBI®，以及新型不可逆半胱氨酸偶联技术 ThiOBI®，以推进下一代 ADC 解决方案。OBI 已开发出一系列下一代 ADC 项目，包括单特异性 ADC，如处于 I 期临床评估阶段的 OBI-902（TROP2）和 OBI-904（Nectin-4）；双特异性单载荷 ADC OBI-201（HER2 × TROP2）；以及双特异性双载荷 ADC OBI-221（cMET × HER3）。为拓展 HYPrOBI® 连接子技术的应用范围，OBI 进一步开发了 ThiOBI® 技术，以实现不可逆的基于半胱氨酸的偶联。除 ADC 项目外，OBI 的资产还包括 OBI-3424，这是一种同类首创的小分子前药，靶向 AKR1C3，可在醛酮还原酶 1C3 高表达的肿瘤中选择性释放强效 DNA 烷化剂。更多信息请访问 www.obipharma.com 。关于 OBI-902 和 OBI-992OBI-902 是一种靶向 TROP2 的抗体药物偶联物（ADC），携带强效拓扑异构酶 I 抑制剂载荷，以药物-抗体比值（DAR）为 4 杀伤肿瘤细胞。TROP2 在多种实体瘤中高度表达，如乳腺癌、肺癌、胆道癌、胆管癌（胆管细胞癌）、卵巢癌、胃癌等多种癌症类型，因此成为理想的癌症治疗靶点。OBI-902 是一种新型位点特异性糖链偶联 ADC，采用 OBI 专有的 GlycOBI® 平台，具有更高的稳定性和更强的亲水性。在多种肿瘤模型中（包括非小细胞肺癌、三阴性乳腺癌和胃癌），OBI-902 展现出显著的抗肿瘤疗效、改进的药代动力学特征以及良好的安全性。其 IND 已于 2025 年 4 月 30 日获得美国食品药品监督管理局（US FDA）批准，并分别于 2025 年 11 月 16 日和 12 月 5 日获得胆管癌及胃癌（包括胃食管结合部癌）的孤儿药资格认定。I/II 期临床试验（NCT07124117）正在进行中，I 期 a 部分预计于 2027 年上半年完成。OBI-992 是另一种靶向 TROP2 的抗体药物偶联物（ADC），通过基于半胱氨酸偶联的亲水性可酶切连接子，以药物-抗体比值（DAR）为 4 携带强效拓扑异构酶 I 抑制剂载荷。OBI-992 在体循环中保持稳定，并将该细胞毒性载荷递送至表达 TROP2 的肿瘤细胞，从而在避免脱靶毒性的同时实现肿瘤细胞杀伤。OBI-992 的 IND 申请已于 2024 年 1 月获得美国 FDA 批准，并于 2024 年 8 月获得用于治疗胃癌（包括 GEJC）的孤儿药资格认定。I/II 期研究（NCT06480240）已达到拟定的 II 期推荐剂量（pRP2D），I 期预计于 2027 年上半年完成。自 2021 年 12 月起，OBI 已获得 Biosion, Inc.（www.biosion.com）授予的 TROP2 靶向抗体氨基酸序列在除中国大陆、香港和澳门以外所有地区的独家许可。Biosion 在中国大陆、香港和澳门拥有该抗体序列的独家权利。OBI 在除中国大陆、香港和澳门以外的所有地区拥有 OBI-992 和 OBI-902 的商业权利，而 Biosion 在中国大陆、香港和澳门拥有相应的商业权利。关于 OBI-904OBI-904 是一种抗体药物偶联物（ADC），由特异性靶向 Nectin-4（Nectin 细胞黏附分子 4）的单克隆抗体构成，通过 OBI 专有的 GlycOBI® ADC 赋能技术，并在双功能酶 EndoSymeOBI® 和新型连接子 HYPrOBI® 的支持下，以药物-抗体比值（DAR）为 8 偶联强效拓扑异构酶 I 抑制剂载荷。该药物有望成为同类首创及同类最佳的基于糖链的 ADC，旨在靶向多种表达 Nectin-4 的癌症类型。在多种动物疾病模型中（包括头颈鳞癌、结直肠癌、三阴性乳腺癌、宫颈癌及肉瘤），其已显示出抗肿瘤活性；在猴重复给药毒性研究中，OBI-904 展现出良好的安全性，目前处于 IND 申请前开发阶段。关于 OBI-201OBI-201 是一种 TROP2 × HER2 双特异性 ADC，基于 OBI 的 GlycOBI® ADC 赋能技术构建，并偶联拓扑异构酶 I 抑制剂。值得注意的是，OBI 首次证明 HER2 与 TROP2 可在细胞表面相互作用并形成蛋白复合物——这一突破性发现得益于与专业 AI 药物研发合作伙伴的协作。与单特异性 TROP2 或 HER2 ADC 相比，OBI-201 具有多项优势。通过同时靶向两种抗原，它可扩大肿瘤覆盖范围，尤其适用于靶点表达异质性或表达水平较低的癌症。双靶向可增强肿瘤选择性、结合亲和力及内吞作用，从而提高载荷向癌细胞的递送效率，同时有望降低对正常细胞的毒性。OBI-201 还可能克服部分单特异性 ADC 治疗后因靶点下调所产生的耐药性。动物研究表明，在 HER2 表达极低的耐药性乳腺癌模型中，OBI-201 相较于单靶点 ADC 展现出显著更优的抗肿瘤活性。OBI-201 能够持续抑制肿瘤生长，显示出其克服多种耐药机制的潜力。OBI-201 是一种新一代双特异性 ADC，有望突破单靶点 ADC 的局限，为患者提供更全面且持久的治疗选择。关于 OBI-221OBI-221 是一种双特异性双载荷 ADC（BsDpADC），基于 OBI 的 GlycOBI DUO® 技术构建，靶向 cMET 和 HER3，并偶联 MMAE 与拓扑异构酶 I 抑制剂双载荷。在临床实践中，靶向 EGFR 的疗法已成为治疗非小细胞肺癌（NSCLC）和结直肠癌（CRC）的关键策略。然而，肿瘤常通过上调 cMET 和 HER3 快速产生耐药性，从而维持肿瘤生长。此外，在胃癌、头颈癌及多种其他实体瘤中也观察到 cMET 和 HER3 的高表达，进一步凸显了未被满足的医疗需求。为应对这一挑战，OBI Pharma 利用其专有的 GlycOBI DUO® 平台和 HYPrOBI® 连接子开发了新型双特异性双载荷抗体药物偶联物（BsDpADC）——OBI-221。该治疗药物可同时靶向 cMET 和 HER3，并递送具有协同作用的细胞毒性载荷，从而有效对抗肿瘤耐药性和异质性。这一突破性设计不仅满足未被满足的医疗需求，也代表了下一代 ADC 开发的前瞻性策略。OBI-221 在克服现有 EGFR 靶向疗法耐药性方面具有重要潜力，有望为患者提供更具针对性的治疗选择，并带来显著的临床价值。关于 GlycOBI®OBI 开发了一种独特的基于糖链的位点特异性 ADC 技术（GlycOBI®），采用即插即用（Plug and Play）设计，可兼容任意抗体、连接子和载荷，并支持多种药物-抗体比值（DAR）（最高可达 16）。该技术由 OBI 专有的双功能酶技术 EndoSymeOBI® 和亲水性连接子技术 HYPrOBI® 驱动，作为 OBI Obrion™ ADC 技术体系的核心组成部分，能够在 GMP 条件下通过高效、可规模化、流程简化的两步一锅法偶联工艺生成位点特异性且高度均一的 ADC。在偶联过程中，GlycOBI® 避免破坏抗体结构，并确保生成的 ADC 保持与天然抗体相当的生物物理特性。此外，OBI 的连接子技术提高了载荷偶联效率，并降低了聚集或降解的倾向，从而进一步支持稳定且可控的 ADC 生产过程。GlycOBI® 克服了传统 ADC 方法常见的局限，并在多项体内研究中展现出更优的抗肿瘤活性和稳定性。值得注意的是，该平台支持偶联细胞毒性小分子抑制剂以及高度疏水性的降解剂，从而拓展至包括 DAC 在内的下一代治疗模式。关于 GlycOBI DUO®GlycOBI DUO® 是一种基于 GlycOBI® 位点特异性偶联平台及其专有酶促偶联策略构建的下一代双载荷抗体药物偶联物（ADC）技术。该技术可在单一抗体上以可调比例精确、可编程地连接两种不同载荷，并支持高 DAR 比值（最高可达 DAR24）。通过结合互补的作用机制，GlycOBI DUO® 旨在增强抗肿瘤疗效、应对肿瘤异质性并提升整体治疗指数，同时具备克服传统 ADC 相关耐药机制的潜力，代表了下一代 ADC 开发的重要进展。关于 ThiOBI®OBI 开发了一种新型不可逆半胱氨酸偶联 ADC 平台（ThiOBI®），具有更高的稳定性，可适用于任意抗体、连接子和载荷。OBI 专有的 ThiOBI® 平台结合连接子技术（HYPrOBI®），可生成多种生物分子形式的 ADC，包括抗体片段、纳米抗体、肽类和蛋白质。此外，OBI 的 HYPrOBI® 连接子技术提高了载荷的偶联效率，降低了聚集倾向，并延长了 ADC 产品的半衰期。ThiOBI 克服了传统半胱氨酸 ADC 的局限，并在多项体内研究中实现了更优的抗肿瘤活性和稳定性。GlycOBI®、EndoSymeOBI®、ThiOBI®、HYPrOBI® 和 GlycOBI DUO® 为 OBI 的注册商标。Obrion™ 为正在申请注册的商标。前瞻性声明本新闻稿中非历史事实的陈述属于《1995 年私人证券诉讼改革法》所定义的前瞻性声明。此类前瞻性声明包括但不限于关于未来临床试验、试验结果及其时间安排的陈述。相关风险因素已在 OBI Pharma 的报告和演示材料中不时披露，包括其向台湾证券期货局提交的文件。公司联系人:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292 jukkamuhonen@obipharma.com来源: OBI Pharma USA, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+A CELLS") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.The GMG G+A CELLS have now demonstrated superior performance characteristics when compared to a representative market leading ultra-fast charging batteries, the Lithium Titanate Oxide ("LTO") batteries, which can be sold at a premium price of up to US$1200/kWh.1Figure 1 shows the current energy density of G+A CELLS, based on BIC testing, and shows the doubling in performance (26 to 49 Wh/kg) since the previous announcement in December 20252 and in comparison, to a representative market leading fast charging high power LTO batteries.Figure 1: Increase in Energy Density for G+A CELLS since December '25 UpdateTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure1.jpgFigure 2 shows the charge and discharge curves for the G+A CELLS when charged in 6 minutes (10C) and 60 minutes (1C). The energy density of the cells for the G+A CELLS when charged in 60 minutes (1C) is now 101 Wh/kg when charging to 100% State of Charge (SOC) which is an increase from 58 Wh/kg from the previous update. This shows the G+A CELLS have a nominal voltage of approximately 3.2 Volts (an increase from 3.0 Volts in the previous update). The G+A CELLS maintained performance over hundreds of cycles at 6-minute fast charging rate (10C).Figure 2: Battery performance curves of G+A CELLS at 60 min and 6min charge (1C & 10C)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_001full.jpgBob Galyen, GMG Non-Executive Director and former CTO of CATL - the largest battery manufacturer in the world, commented: "With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems and or combinatorial systems with multiple battery technologies while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Standard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are NOT designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).3GMG has now developed a completely new hybrid electrolyte that is chloride free and non-corrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over hundreds of cycles. The substrate for both the cathode and anode in the G+A CELLS is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.GMG believes that it has significantly met the key target specification requirements for use in heavy mobile equipment, as shown in Figure 3, its main targeted use case, including:- Charging in under 6 minutes;- Energy density > 100 Wh/kg after 1 hour of charging; and- Safe (no Lithium).The next battery development steps include the following activities:- Test and show cycle life up to 10,000 cycles- Test and show ambient temperature impacts- Test and show standard safety testing- Test and show no thermal battery management system needed  Figure 3: G+A CELLS Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure3.jpgCraig Nicol, GMG Managing Director and CEO, commented: "This is a significant step up from where we were at with battery performance in December 2025 and we see the required performance for our targeted use case being largely met - which means we can start to put together the next stages of the battery maturation program - including partnerships and manufacturing plans."GMG management believes that the G+A CELLS can eventually achieve over 160 Wh/kg when charged in 1 hour, and over 80 Wh/kg when charged in 6 minutes with further development of the cathode, anode, electrolyte and component weights.Figure 4 shows the latest G+A CELLS in pouch format:Figure 4: Current Multi-Layer G+A CELLTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure4.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+A CELLS remains at Level 4, whilst significantly progressed through this level as shown in Figure 5. GMG is currently in the process of completing the optimization of the electrochemical behaviour for the pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will ultimately progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+A CELLS are the same as those employed to make Lithium-Ion Batteries, though no definitive timeline for achievement can be provided at this time.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_004full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_005full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Non-Executive Chairman and Director, commented: "I am extremely proud that GMG has progressed its battery to this stage - the Company is getting very close to final commercialisation steps. We look forward to providing further updates as GMG progresses the development of its battery technology."The Company continues to see a broad range of potential applications for a completed G+A CELLS - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_006full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity relative to using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of G+A CELL packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for GMG's G+A CELLS Pouch FormatTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_007full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+A CELL technology is already very similar to representative LTO batteries.Figure 9: Comparison of GMG's G+A CELLS to Lithium Titanate Oxide (LTO) BatteryTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure9.jpg LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for G+A CELLS are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.6 The LTO product is sold globally for use in many applications — with a total of US$5.67 billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 16.9% per annum to an estimated US$ 12.5 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+A CELLS can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+A CELLS battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+A CELLS Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/Dec 2025GMG Unveils Graphene Aluminium-Ion Battery that Fully Charges in 6 minuteshttps://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the pricing of LTO batteries, expectations for GMG G+AI batteries to achieve specification requirements for heavy mobile equipment, the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, stability, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.1 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.2 https://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/3 https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt4 High-power type cells | SCiB™ Rechargeable battery | Toshiba5 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.6 https://www.grepow.com/blog/battery-energy-density.html7 Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/292641 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TW, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904.We are further advancing precision oncology through our next-generation bispecific (OBI-201) and bispecific, dual-payload (OBI-221) ADCs. These "biology - driven" molecules are designed to overcome tumor heterogeneity and multi-drug resistance-key challenges in current cancer treatment. By incorporating both the GlycOBI® and GlycOBI DUO® platforms, OBI is developing novel and differentiated therapeutics addressing the unmet medical need for patients with difficult-to-treat solid tumors. Additionally, OBI's robust ADC conjugation platform has proven to consistently deliver product quality and scalability, while enabling expansion into next-generation modalities, including degrader-antibody conjugates (DACs).These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 17 to 22, 2026 in San Diego, CA. (USA)."At OBI, we make better ADCs," said Dr. Ya-Chi Chen, Chief Scientific Officer OBI Pharma. "Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options."Monday, April 20, 2026 (9:00 AM - 12:00 PM)Title: Overcoming Resistance with OBI-902: Preclinical Evaluation of a Next-Generation TROP2 ADC1Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO. ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 6Abstract Presentation Number: 1818Title: OBI-904, a Next-Generation Nectin-4-Targeting Exatecan ADC, Demonstrates Enhanced Cytotoxicity and Overcomes Enfortumab Vedotin Resistance2Authors :Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 26Abstract Presentation Number: 1729Title: OBI-904, a Glycan-based Site specific Nectin-4-Targeted ADC, Demonstrates Potent and Durable Antitumor Activity with an Improved PK Profile and Overcoming EV-Resistance in Non-Clinical Studies3Authors: Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 7Abstract Presentation Number: 1819Title: The MET/HER3 Antibody-Drug Conjugate with Dual Payload: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms5Authors: Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.CL.0705 - Targeted Antigen Therapies and ImmunityLocation: Poster Section 49Poster Board Number: 17Abstract Presentation Number: 2665Title: Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery6Authors: Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen .OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number : 27Abstract Presentation Number: 1730Title: Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader-Antibody Conjugates with Improved Stability and Enhanced Activity7Authors: Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 28Abstract Presentation Number: 1731Title: Cell-based payload release highlights design, site, and cell-dependent ratio shifts in dual-payload ADCs8Authors: Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.CH01.06 - Antibodies, Antibody-Drug Conjugates, and Nucleic AcidsLocation: Poster Section 38Poster Board Number: 5Abstract Presentation Number: 2397Monday, April 20, 2026 (2:00 PM - 5:00 PM)Title:TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance4Authors: Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET03.06 Drug Resistance 1: Antibodies and ADCsLocation: Poster Section 12Poster Board Number: 18Abstract Presentation Number: 2972Tuesday, April 21, 2026 (9:00 AM - 12:00 PM)Title: Glycan-based site specific ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation9Authors: Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.IM02.04 - Adaptive Immunity in CancerLocation: Poster Section 6Poster Board Number: 2Abstract Presentation Number: 4234Title: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility10Authors: Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen,Teng-Yi Huang. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.03 - Antibody-Drug Conjugates and Linker Engineering 3Location: Poster Section 12Poster Board Number: 1Abstract Presentation Number: 4423The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.1 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5403About OBI PharmaOBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.OBI's research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel irreversible cysteine-conjugation technology ThiOBI® , to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2), which is under Ph1 clinical evaluation, and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI® linker technology, OBI has further developed the ThiOBI® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI's assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.About OBI-902 and OBI-992OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy across multiple tumors, including NSCLC, triple-negative breast cancer (TNBC), and gastric cancer, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the United States Food and Drug Administration (US FDA) on April 30, 2025, received Orphan Drug Designation (ODD) from the US FDA for cholangiocarcinoma on Nov. 16, 2025, and gastric cancer (GC), including gastroesophageal junction cancer (GEJC) on December 5, 2025.The Phase 1/2 Study (NCT07124117) is ongoing, with completion of the Phase 1a portion targeted for 1H 2027.OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload with drug-to-antibody ratio of 4 (DAR 4) via a cysteine conjugated, hydrophilic and enzyme-cleavable linker. OBI-992 remains stable in circulation and delivers this cytotoxic payload to TROP2-expressing tumor cells, leading to tumor cell death while avoiding off-target toxicities.The US FDA cleared the IND application for OBI-992 in Jan 2024 and subsequently granted Orphan Drug Designation for the treatment of gastric cancer, including GEJC in Aug 2024. The Phase 1/2 Study (NCT06480240) has reached the putative Recommended Phase 2 Dose (pRP2D) and Phase I completion is targeted for 1H 2027.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive license to a TROP2 targeting antibody amino acid sequence in all jurisdictions except Mainland China, Hong Kong and Macau. Biosion holds exclusive rights to that antibody sequence in Mainland China, Hong Kong and Macau. OBI holds commercial rights to OBI-992 and OBI-902 in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion holds commercial rights to OBI-992 and OBI-902 in Mainland China, Hong Kong and Macau.About OBI-904OBI-904 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody specifically targeting Nectin-4 (Nectin cell adhesion molecule 4), linked to a potent topoisomerase I inhibitor payload with Drug-to-Antibody Ratio of 8 (DAR8) through OBI's proprietary GlycOBI® ADC enabling technologies, powered by a dual-function enzyme, EndoSymeOBI®, and a novel linker, HYPrOBI®. It is a potentially first-in-class and best-in-class glycan-based ADC designed to target multiple cancer types that express Nectin-4. Antitumor activity has been shown across several animal disease models, including HNSCC, CRC, TNBC, cervical and sarcoma cancers; OBI-904 has demonstrated a favorable safety profile in a repeat dose toxicity study in monkeys, and is now in the pre-IND stage of development.About OBI-201OBI-201 is a TROP2 x HER2 bispecific ADC generated by OBI GlycOBI® ADC enabling technologies conjugated with a topoisomerase I inhibitor. Notably, OBI is the first to demonstrate that HER2 and TROP2 can interact and form a protein complex on the cell surface-a groundbreaking discovery facilitated through collaboration with a specialized AI drug discovery partner. OBI-201 offers several advantages over mono-specific TROP2 or HER2 ADCs. By targeting both antigens, it broadens tumor coverage, especially in cancers with heterogeneous or low expression of either target. Dual targeting can enhance tumor selectivity, binding avidity, and internalization, improving payload delivery to cancer cells while potentially reducing toxicity to normal cells. OBI-201 may overcome resistance associated with downregulation of targets after treatment by certain monospecific ADCs.Animal studies revealed that OBI-201 demonstrated significantly superior anti-tumor activity compared to single-target ADCs in drug-resistant breast cancer models with extremely low HER2 expression. OBI-201 was able to sustain tumor growth suppression, indicating its potential to overcome multiple drug-resistance mechanisms. OBI-201 is a next-generation bispecific ADC poised to break through the limitations of single-target ADCs, potentially offering patients a more comprehensive and durable treatment option.About OBI-221OBI-221 is a Bispecific-Dual Payload ADC (BsDpADC), generated by OBI GlycOBI DUO® technologies, targeting cMET and HER3, conjugated with dual payload of MMAE and topoisomerase I inhibitor.In clinical practice, EGFR-targeted therapies have become a key strategy for treating non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. However, tumors often rapidly develop resistance by upregulating cMET and HER3 that, in turn, sustain tumor growth. Moreover, high expressions of cMET and HER3 have been observed in gastric cancer, head and neck cancer, and various other solid tumors, further underscoring the unmet medical needs.To address this challenge, OBI Pharma leverages its proprietary GlycOBI DUO® platform and HYPrOBI® linker to develop a novel bispecific dual-payload antibody-drug conjugate (BsDpADC)-OBI-221. This therapeutic agent simultaneously targets cMET and HER3 while delivering synergistic cytotoxic agents, effectively combating tumor resistance and heterogeneity. This breakthrough design not only addresses an unmet medical need but also represents a forward-looking strategy for next-generation ADC development.OBI-221 holds meaningful potential to overcome resistance to existing EGFR-targeted therapies, potentially offering patients more targeted treatment options while delivering substantial clinical value.About GlycOBI®OBI has developed a unique glycan-based, site-specific ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR)(up to 16). Powered by OBI's proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI's Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs through an efficient, scalable and streamlined two-step, one-pot conjugation process under GMP conditions.During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI's linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies. Notably, the platform supports the conjugation of both cytotoxic small-molecule inhibitors and highly hydrophobic degraders, expanding its applicability to next-generation modalities such as DACs.About GlycOBI DUO®GlycOBI DUO® is a next-generation dual-payload antibody-drug conjugate (ADC) technology built on the GlycOBI® site-specific conjugation platform and its proprietary enzymatic conjugation strategy. It enables the precise and programmable attachment of two distinct payloads to a single antibody with tunable ratios and supports high DAR ratios, including up to DAR24. By combining complementary mechanisms of action, GlycOBI DUO® is designed to enhance antitumor efficacy, address tumor heterogeneity, and improve the overall therapeutic index, with the potential to overcome resistance mechanisms associated with conventional ADCs-representing a promising advancement in next-generation ADC development.About ThiOBI®OBI has developed a novel irreversible, cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. OBI's proprietary ThiOBI® platform including linker technologies (HYPrOBI®) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI's HYPrOBI® linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity and also expanded the half-life of the ADC products. ThiOBI has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests.GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292jukkamuhonen@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亚太商讯 via SeaPRwire.com) - 品创控股有限公司（"品创控股"或"公司"，连同其附属公司统称为"集团"；股份代号：8066）欣然宣布，集团全资附属公司赛博幻境（香港）有限公司（"赛博幻境"）于今日隆重举行《语音 AI 之 Echo 生态战略全球启幕盛典》，正式启动其全球语音 AI 回声生态系统（Echo Ecosystem，"回声生态"）战略，构建从语音数据采集、处理到商业应用的全链路闭环。此举标志着集团在人工智能语音数据服务领域的战略布局迈入全新阶段，为集团深化 AI 业务转型、打造长效增长曲线奠定坚实基础。针对语音数据采集规模、质量与多样性的行业困境，赛博幻境创造性推出区块链游戏与语音数据采集相结合的全新模式。用户参与游戏时，完成指定文本的语音录制任务，既可享受游戏乐趣，亦可获得代币激励。该"游戏化采集"模式，可大规模、高效率获取覆盖不同年龄、地域、口音与情感表达的真人语音数据，为构建多元化声音数据库提供稳定持续的来源。采集完成后，回声平台透过专业清洗、标注与分类处理，将原始语音转化为可直接用于 AI 训练的结构化声音数据库。相关数据库于 AI 数据市场以回声代币交易，供全球开发者及企业采购使用，形成"用户参与采集 — 获取代币激励 — 数据加工处理 — 市场交易流通 — 产业应用赋能"的完整价值链闭环。该模式不仅大幅降低语音 AI 开发门槛，更让数据贡献者、开发者及终端用户共享语音 AI 发展所带来的裨益。"语音 AI 不仅是技术，更是未来数字世界的入口。"赛博幻境首席执行官郭晓鹏先生在盛典上表示，"回声生态致力于构建语音 AI 时代的基础设施，透过去中心化的数据采集网络和开放的声音数据库市场，我们将为全球 AI 开发者提供最丰富、最优质的声音数据资源，推动语音 AI 技术在各行各业的快速落地和应用创新。"当前，人工智能技术加速渗透各行各业，人机对话已成为 AI 应用场景的核心交互方式。语音 AI 技术作为 AI 智能体不可或缺的组成部分，正成为连接人类与数字世界的入口。高品质、多元化的声音数据库是 AI 智能体强化训练的核心基础，语音 AI 技术发展已进入"数据驱动"新阶段，优质声音数据库不仅可显著提升语音合成的情感表现力、语音识别的场景适应性与对话系统的个性化能力，更成为语音 AI 产业发展的核心竞争力与先发优势所在。品创控股锐意推动业务多元化布局，把握数字经济与人工智能产业的蓬勃商机，并凭借前瞻性转型，成功构建"私域电商营运+AI技术服务"双轮驱动的业务架构。本次回声生态全球启动，是集团深化AI业务布局、推动主营业务向AI数据服务转型的关键里程碑。展望未来，集团将以赛博幻境为核心载体，持续深耕语音AI技术研发，拓展生态合作网络，推动技术在智能客服、数字人、元宇宙、智能汽车等前沿领域深度融合；同时深化两大业务协同效应，强化核心竞争力，推动业务高质量发展，把握全球AI产业广阔机遇，致力为股东创造可持续长期回报。图片说明赛博幻境首席执行官郭晓鹏先生讲解去中心化语音网络的价值实现，彰显品创控股推动语音 AI 技术在各行各业的快速落地和应用创新的决心。关于品创控股有限公司品创控股有限公司的使命是妥善运用公司所获得的资本与独特投资机会，为股东提供稳定的优渥收入与获利。品创控股由六个主要事业部门组成，包括智能卡制造服务、电子商务、人工智能、投资服务、资源回收投资与媒体与娱乐投资，主要业务为生产及销售智能卡、提供定制智能卡应用系统、私域电子商务平台营运、人工智能语音技术数据服务、提供财务及管理咨询服务、废旧金属销售及贸易、以及媒体与娱乐行业之投资。公司的总部位于香港，旗下控股公司与投资则遍布大中华地区。关于赛博幻境（香港）有限公司赛博幻境（香港）有限公司是品创控股有限公司的全资子公司，专注于语音人工智能技术的研发与应用。赛博幻境致力于通过创新的生态模式，打造从数据采集、处理到商业落地的全链条语音AI解决方案，助力全球智能语音产业的发展。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亚太商讯 via SeaPRwire.com) - 中国领先循环经济产业新消费公司转转集团（下称：转转）近日宣布，其自主研发的AI鉴定产品「AI拍图验真」已在二手奢侈品鉴定领域取得重大突破，鉴定准确率实现了LV包袋鉴定错误率不足万分之一、GUCCI包袋零错误的卓越表现；鉴定效率提升近900倍至「1秒出结果」。集团今年将逐步把AI鉴定拓展至CHANEL、Hermès等热门品牌，并于未来延伸至腕表等其他二手品类，构建全品类AI鉴定矩阵。凭借其顶尖AI鉴定能力及创新业务模式的领先优势，转转同步计划在香港设立国际业务总部，正式开启全球化布局。作为中国头部二手交易平台，转转自2015年成立以来发展迅速，旗下拥有转转、找靓机、红布林等多个知名二手消费品牌。当前中国二手闲置赛道备受资本与市场瞩目，转转亦凭借首创的二手质检「官方验」服务脱颖而出。集团已获包括腾讯、小米、58集团在内的多个知名企业或投资者支持，上一轮融资估值达逾30亿美元（约234亿港元），去年营收总额突破200亿元人民币，拥有超过4亿注册用户、5,000万月活跃用户。 （图为北京「超级转转」二奢仓店）有别于以Carousell、闲鱼等企业为代表的传统C2C模式，转转透过成熟的C2B2C商业模式，以「平台居中、专业鉴定、品质保证」提供差异化平台服务。其首创的「官方验」服务会在对回收商品全方位严格检测后为其提供一份专属的质检报告并公开展示，绝大部分官方验商品，都可享有7天无理由退货、一年平台质保、内陆包邮等增值服务。转转透过标准化质检与售后保障，例如履行「验了再发货」、「不满意可退」、「验错了就赔」等策略，为消费者提供「所见即所得」的优质体验。 （图为转转青岛智能质检中心）技术驱动是转转稳居行业领先地位的核心引擎。转转去年成立了AI事业部，三年内拟投入20亿元人民币研发AI质检、智能匹配等工具。今年初上线的「AI拍图验真」，深度应用于二手奢侈品鉴定领域，系统基于海量真实商品图片数据库与深度学习算法，将传统需时15分钟的人工鉴定大幅压缩至「秒级鉴定」，最快1秒即可出结果，效率提升近900倍;同时在核心包袋品类的鉴定上，更创下错误率不足万分之一的超高准确率（上线至今，LV包袋累计鉴定逾万单，仅错一单，错误率不足万分之一），彻底打破了传统非标品交易及人工鉴定中的标准不一、效率樽颈等难题。转转集团创办人兼行政总裁黄炜表示：「转转集团在过去十年间通过持续的技术创新和战略整合，确立了在中国二手交易市场的领导地位，我们深信领先的技术与质检能力是打破二手交易壁垒的关键。转转致力引领中国的二手消费模式，不断刷新消费者的二手消费体验，我们对即将在香港设立国际业务总部感到振奋，亦是标志着转转从中国市场迈向国际舞台的重要里程碑。」 （图为转转APP内商品AI鉴定信息）关于转转转转集团成立于2015年，是中国领先的循环经济产业新消费公司，旗下拥有转转、找靓机、采货侠、侠客汇、红布林等多个二手电商品牌，业务覆盖手机3C、奢侈品、图书、潮玩等百余种余种品类二手商品交易，在全国布局超过1,100多家线下门店和超过3,000人的上门回收团队，通过人工智能质检技术和创新的C2B2C商业模式，致力解决非标品交易的信任难题，为消费者带来有质价比的二手好物。转转作为全国有履约二手商品交易平台的领导企业，去年已录得超过4亿注册用户、5000万月活跃用户。「技术驱动+平台服务」为核心引擎，转转特设AI事业部，在国立首创二手质检「官方验」服务，并先后自主研发AI估价系统、AI拍图验真等核心技术产品，打造了二奢行业的顶尖AI鉴定能力，为全球知名热门的奢侈品牌包袋品类提供秒级且精准的真伪鉴定，持续引领中国二手交易市场向标准化、数字化迈进。传媒垂询，请联络：转转集团公关部 Alan Wei：weixi@zhuanzhuan.com  Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - As artificial intelligence adoption accelerates across Southeast Asia, enterprises across the ASEAN region are increasingly establishing structured AI engineering practices to move from experimentation to production-scale deployment.According to Joseph Bosco, Partner Manager, APJ - Prof Services at Databricks, organisations across ASEAN are recognising that sustainable AI adoption depends not only on advanced models but also on robust engineering foundations that ensure reliability, governance and operational scalability.“The early phase of AI adoption focused heavily on experimentation and proofs of concept,” Bosco said. “Across Southeast Asia we are now seeing a shift towards AI engineering practices that prioritise data quality, governance and production readiness.”Markets such as Singapore, Indonesia, Vietnam, Malaysia and Thailand are witnessing strong momentum in enterprise AI adoption as organisations modernise their data infrastructure and invest in advanced analytics capabilities.Industry experts note that AI engineering is becoming a critical discipline that connects AI innovation with enterprise operations. This includes building scalable data pipelines, managing machine learning lifecycle processes and integrating AI systems into business workflows.“Building a model is only one part of the challenge,” Bosco said. “The real work lies in creating reliable data pipelines, managing model lifecycle and embedding AI into operational systems.”Across ASEAN, many enterprises continue to manage complex data environments spanning legacy systems, multiple cloud platforms and software-as-a-service applications. Consolidating these fragmented data sources into unified platforms is increasingly seen as a prerequisite for scaling AI initiatives.Technology partners and consulting firms across the region are responding by developing dedicated AI engineering practices that combine expertise in data engineering, machine learning, generative AI and governance frameworks.These capabilities are already being applied across key sectors including financial services, telecommunications, and manufacturing.Bosco noted that Southeast Asia’s rapidly expanding data economies are creating a particularly dynamic environment for AI engineering talent and innovation.“As organisations across ASEAN continue to invest in data transformation, AI engineering will become an essential capability that enables enterprises to operationalise AI safely and effectively,” he said. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com